Nektar Therapeutics Faces Class Action Over Failed Trial Enrollment Claims

Pomerantz LLP has filed a class action lawsuit against Nektar Therapeutics, Inc. ($NKTR) and certain company officers, alleging securities fraud stemming from misrepresentations about patient enrollment procedures in a critical clinical trial. The lawsuit centers on the REZOLVE-AA trial for rezpegaldesleukin, which failed to achieve statistical significance after the company's enrollment protocols allowed four ineligible patients to participate in the study. The disclosure of these enrollment failures triggered a sharp market reaction, with Nektar's stock declining 7.77% on December 16, 2025, as investors reassessed the company's governance practices and the viability of a key pipeline asset.

The legal action underscores growing scrutiny of clinical trial management practices within the biotechnology sector and raises questions about the adequacy of internal controls at mid-cap pharmaceutical companies. For Nektar, a company heavily dependent on its late-stage pipeline for future revenue growth, the failed trial represents both a clinical setback and now a legal liability that could extend far beyond the immediate market reaction.

The Trial Failure and Alleged Misconduct

The REZOLVE-AA clinical trial was designed to evaluate rezpegaldesleukin, an immunotherapy candidate, in patients with a specific indication. According to the lawsuit allegations, Nektar Therapeutics made representations to investors regarding the enrollment procedures and the integrity of patient screening protocols used in the trial. However, subsequent investigation revealed that four patients who did not meet the trial's eligibility criteria were enrolled in the study.

This enrollment breach had material consequences for the trial's outcomes:

• The inclusion of ineligible patients compromised the statistical validity of the results
• The trial failed to reach statistical significance, a critical benchmark for advancing to regulatory review
• The disclosed procedural failures raised questions about quality assurance mechanisms within the company's clinical operations
• Investors were not contemporaneously informed of the enrollment issues, according to the complaint

The failure of REZOLVE-AA represents a significant setback for Nektar's pipeline. Immunotherapy candidates in this space are among the company's most advanced programs, and trial failures directly impact valuation models and near-term revenue prospects. For a company with limited near-term cash flow from approved products, the loss of a promising candidate can materially affect shareholder returns and capital allocation decisions.

Market Context and Industry Implications

The securities fraud allegations against Nektar Therapeutics arrive amid heightened scrutiny of clinical trial management practices across the biotechnology industry. The FDA and investor community have become increasingly attentive to trial governance following several high-profile cases where procedural failures undermined the credibility of study results.

Nektar Therapeutics operates in a highly competitive immunotherapy landscape dominated by well-capitalized players such as Merck ($MRK), Bristol Myers Squibb ($BMY), and Regeneron ($REGN). The company's ability to advance differentiated pipeline candidates is essential to justify its market valuation and compete for institutional investment. A loss of investor confidence in management's operational oversight and disclosure practices could impact the company's ability to fund development programs and attract partnership opportunities.

The timing of the December 2025 disclosure and subsequent stock decline reflects the market's swift repricing of risk. Biotechnology investors typically apply significant discounts to companies following governance failures or clinical setbacks, particularly when internal control weaknesses are revealed. The 7.77% single-day decline suggests the market recognized material negative implications for the company's credibility and near-term prospects.

From a regulatory perspective, the enrollment failures may also trigger FDA scrutiny. The agency has authority to audit clinical trial sites and operations, and material deviations from approved protocols can result in additional regulatory actions, potential clinical hold orders, or requests for enhanced monitoring in subsequent trials.

Investor Implications and Shareholder Risk

The class action lawsuit exposes Nektar Therapeutics shareholders to multiple categories of risk:

Litigation Risk: Class actions against publicly traded companies can result in substantial settlements or judgments, potentially draining capital that would otherwise fund R&D or shareholder distributions. Legal fees and management distraction also impose non-quantifiable costs.

Valuation Impact: Investors may apply higher risk premiums to Nektar's clinical candidates, particularly earlier-stage programs where governance concerns could influence FDA interactions. This could suppress the stock price and increase the company's cost of capital for future financing.

Pipeline Risk: The failure of REZOLVE-AA eliminates a potential revenue stream and forces management to redirect resources. If additional pipeline candidates depend on similar trial designs or enrollment procedures, investors may question their validity.

Management Credibility: Securities fraud allegations, even if ultimately unproven, damage management's credibility with investors, regulators, and potential partners. This can complicate business development efforts and financing activities.

For long-term shareholders, the key question is whether this incident reflects systemic management weaknesses or an isolated operational lapse. If the former, further deterioration in pipeline confidence may be forthcoming. Conversely, if Nektar demonstrates swift remedial action and reinforces governance practices, the company could stabilize investor sentiment over time.

Institutional investors holding Nektar stock face pressure to reassess portfolio exposure and may use the litigation as an opportunity to exit positions at depressed valuations, potentially amplifying downward pressure on the stock.

Looking Ahead: Recovery and Regulatory Path

Nektar Therapeutics faces a multifaceted challenge in rebuilding investor confidence. The company must address the immediate legal and reputational fallout while simultaneously advancing remaining pipeline candidates and demonstrating operational improvements. Management's response to the allegations—through remedial actions, governance reforms, and transparent communication—will significantly influence the trajectory of the stock and the company's long-term viability.

The outcome of the Pomerantz class action will likely depend on evidence regarding what management knew about enrollment procedures and when such knowledge existed. If discovery reveals systemic indifference to protocol violations, the liability exposure could be substantial. Conversely, if the enrollment failures were genuinely isolated and promptly remediated upon detection, the company may achieve a more favorable settlement or dismissal.

Investors should monitor developments closely, including any additional clinical trial disclosures, regulatory communications from the FDA, and settlement negotiations. The broader lesson from this case is that biotechnology investors cannot assume clinical governance is uniform across the industry; due diligence on operational controls and management oversight remains essential for risk assessment.

For the biotechnology sector overall, the Nektar case reinforces that enrollment integrity and trial governance are not merely operational matters—they are fundamental to investor trust and shareholder value preservation.